From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
NYHA Class
Placebo/Routine Care
Levamisole/ Routine Care
Day 1
Day 14
N (%)
Class I (Mild)
12
0
11
Class II (Mild)
Class III (Moderate)
8
4
Class IV (Severe)
5
3
6